Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus carboplatin and etoposide in first-line extensive-stage small cell lung cancer
CTR20261584Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PF-08634404 in small cell lung cancer (SCLC), sponsored by Pfizer. Started Sep 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20261584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261584.